96 related articles for article (PubMed ID: 11496328)
1. Expression of tumor-associated glycoprotein-72 (TAG-72) antigen in human prostatic adenocarcinomas.
Karan D; Johansson SL; Lin MF; Batra SK
Oncol Rep; 2001; 8(5):1123-6. PubMed ID: 11496328
[TBL] [Abstract][Full Text] [Related]
2. Expression of tumor-associated glycoprotein 72 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.
Myers RB; Schlom J; Srivastava S; Grizzle WE
Mod Pathol; 1995 Apr; 8(3):260-5. PubMed ID: 7617651
[TBL] [Abstract][Full Text] [Related]
3. Tumor associated glycoprotein-72 is highly expressed in prostatic adenocarcinomas.
Myers RB; Meredith RF; Schlom J; LoBuglio AF; Bueschen AJ; Wheeler RH; Stockard CR; Grizzle WE
J Urol; 1994 Jul; 152(1):243-6. PubMed ID: 8201675
[TBL] [Abstract][Full Text] [Related]
4. TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49.
Brenner PC; Rettig WJ; Sanz-Moncasi MP; Reuter V; Aprikian A; Old LJ; Fair WR; Garin-Chesa P
J Urol; 1995 May; 153(5):1575-9. PubMed ID: 7536270
[TBL] [Abstract][Full Text] [Related]
5. Prostatic adenocarcinoma. Evaluation of immunoreactivity to monoclonal antibody B72.3.
Mazur MT; Shultz JJ
Am J Clin Pathol; 1990 Apr; 93(4):466-70. PubMed ID: 2321578
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of topoisomerase II alpha and Her-2/neu in prostatic carcinoma and benign prostatic hyperplasia.
Hasby EA; Saied EM
J Egypt Natl Canc Inst; 2008 Jun; 20(2):158-67. PubMed ID: 20029472
[TBL] [Abstract][Full Text] [Related]
7. Expression analysis of putative stem cell markers in human benign and malignant prostate.
Ugolkov AV; Eisengart LJ; Luan C; Yang XJ
Prostate; 2011 Jan; 71(1):18-25. PubMed ID: 20583131
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas.
Beckett ML; Lipford GB; Haley CL; Schellhammer PF; Wright GL
Cancer Res; 1991 Feb; 51(4):1326-33. PubMed ID: 1705172
[TBL] [Abstract][Full Text] [Related]
9. Complementary reactivities of anti-carcinoembryonic antigen and antitumor-associated glycoprotein 72 monoclonal antibodies in lung carcinomas.
Battista P; Muraro R; Mammarella S; Curia MC; Colasante A; Rosini S; Lesti G; Sacco R; French D; Frati L
Cancer Res; 1990 Nov; 50(21):6987-94. PubMed ID: 1698547
[TBL] [Abstract][Full Text] [Related]
10. Lewis Y antigen as detected by the monoclonal antibody BR96 is expressed strongly in prostatic adenocarcinoma.
Myers RB; Srivastava S; Grizzle WE
J Urol; 1995 May; 153(5):1572-4. PubMed ID: 7714977
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
[TBL] [Abstract][Full Text] [Related]
12. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.
Marchal C; Redondo M; Padilla M; Caballero J; Rodrigo I; García J; Quian J; Boswick DG
Histol Histopathol; 2004 Jul; 19(3):715-8. PubMed ID: 15168332
[TBL] [Abstract][Full Text] [Related]
13. Applications of monoclonal antibodies in clinical cytology as exemplified by studies with monoclonal antibody B72.3. The George N. Papanicolaou award lecture.
Johnston WW
Acta Cytol; 1987; 31(5):537-56. PubMed ID: 3314301
[TBL] [Abstract][Full Text] [Related]
14. EBAG9/RCAS1 expression and its prognostic significance in prostatic cancer.
Takahashi S; Urano T; Tsuchiya F; Fujimura T; Kitamura T; Ouchi Y; Muramatsu M; Inoue S
Int J Cancer; 2003 Sep; 106(3):310-5. PubMed ID: 12845666
[TBL] [Abstract][Full Text] [Related]
15. Complementation of expression of carcinoembryonic antigen and tumor associated glycoprotein-72 (TAG-72) in human colon adenocarcinomas.
Simpson JF; Primus FJ; Schlom J
Int J Biol Markers; 1991; 6(2):83-90. PubMed ID: 1716293
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical localization of prostate-specific acid phosphatase and prostate-specific antigen in stage A2 adenocarcinoma of the prostate: prognostic implications.
Epstein JI; Eggleston JC
Hum Pathol; 1984 Sep; 15(9):853-9. PubMed ID: 6381284
[TBL] [Abstract][Full Text] [Related]
17. Muscarinic M3 acetylcholine receptor immunostaining in paraffin-embedded normal and neoplastic prostatic gland tissue.
Blanco M; Robinson MJ
Ann Diagn Pathol; 2004 Dec; 8(6):333-6. PubMed ID: 15614736
[TBL] [Abstract][Full Text] [Related]
18. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3.
Thor A; Ohuchi N; Szpak CA; Johnston WW; Schlom J
Cancer Res; 1986 Jun; 46(6):3118-24. PubMed ID: 3516392
[TBL] [Abstract][Full Text] [Related]
19. RM2 antigen (beta1,4-GalNAc-disialyl-Lc4) as a new marker for prostate cancer.
Saito S; Egawa S; Endoh M; Ueno S; Ito A; Numahata K; Satoh M; Kuwao S; Baba S; Hakomori S; Arai Y
Int J Cancer; 2005 May; 115(1):105-13. PubMed ID: 15704108
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
Lane Z; Hansel DE; Epstein JI
Am J Surg Pathol; 2008 Sep; 32(9):1322-6. PubMed ID: 18670358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
